Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 82 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diphtheria Clear all

Conditions: Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions: AFIX Only, AFIX+ Provider Communication Training; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Meningitis, Meningococcemia
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 13 Years to 21 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 9
States / cities: Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 6 more

Conditions: Diphtheria, Polio, Pertussis
Interventions: DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 36
States / cities: Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more

Conditions: Pertussis
Interventions: TDAP; Biological
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Durham, North Carolina • Nashville, Tennessee

Conditions: Maternal Immunization
Interventions: Prevention, Maternal Immunization; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 15 Years and older · Female only
Enrollment: 1,350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Meningitis, Meningococcal Disease
Interventions: None administered in this study; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 62,626 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Acellular Pertussis, Tetanus, Diphtheria
Interventions: Taking of blood samples, Boostrix, Adacel; Procedure · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 28 Years to 73 Years
Enrollment: 1,954 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 37
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 31 more

Conditions: Acellular Pertussis, Tetanus, Diphtheria
Interventions: Boostrix®, Menactra™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 1,344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 24
States / cities: Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more

Conditions: Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 1,345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more

Conditions: Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Interventions: Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 15 Months
Enrollment: 852 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 49
States / cities: Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more

Conditions: Group B Streptococcus Infections
Interventions: Multivalent Group B streptococcus vaccine, Tetanus, diphtheria, and acellular pertussis vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more

Conditions: Apnea, Apnea Neonatal, Prematurity
Interventions: PCV13, DTaP, HBV, IPV, Hib; Biological
Lead sponsor: Duke University; Other
Eligibility: 6 Weeks and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Tetanus, Acellular Pertussis, Diphtheria
Interventions: GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 478 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Antioch, California • Daly City, California • Hayward, California + 7 more

Conditions: Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions: Boostrix®, Decavac™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 1,332 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 24
States / cities: Tucson, Arizona • Los Angeles, California • DeLand, Florida + 21 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT vaccine, dTpa vaccine; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Years to 49 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami, Florida • Beaumont, Texas

Conditions: Pregnancy
Interventions: Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio

Conditions: Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions: Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 4 Years to 7 Years
Enrollment: 882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 26
States / cities: Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more

Conditions: Meningitis, Meningococcal Disease
Interventions: None administered in this study; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 1,421 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Diphtheria, Tetanus, Pertussis, Polio, Haemophilus Infection
Interventions: Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 989 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 19
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Oakland, California + 16 more

Conditions: Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions: DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 5 Days
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Torrance, California

Conditions: HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 38
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more

Conditions: Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions: Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 18 Months
Enrollment: 1,394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more

Conditions: Acellular Pertussis, Diphtheria, Tetanus
Interventions: Boostrix™, ADACEL®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 64 Years
Enrollment: 2,337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 42
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 36 more

Conditions: Pertussis, Tetanus, Diphtheria
Interventions: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 647 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Annapolis, Maryland • Baltimore, Maryland • Frederick, Maryland + 6 more

Search by objective public record fields.

High and Low Resource Interventions to Promote HPV Vaccines

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Safety and Immune Response of Different Pediatric Combination Vaccines.

TDAP Safety in Pregnant Women

Adapting Motivational Interviewing for Maternal Immunizations (MI4MI)

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™

Pentavalent DTaP-Hep B-IPV

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®